Kazia Therapeutics Annual Report 2021

2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 55 Movements in ordinary share capital Details Date Shares Issue price $ Balance 1 July 2019 62,166,673 36,641,519 Share placement 1 November 2019 10,000,000 $0.400 4,000,000 Share placement 16 April 2020 18,041,667 $0.400 7,216,667 Issued under Share Purchase Plan 11 May 2020 4,390,010 $0.400 1,756,004 Issued on conversion of options 19 $4.000 76 Less: share issue transaction costs - $0.000 (833,052) Balance 30 June 2020 94,598,369 48,781,214 Issued on conversion of options 28 August 2020 25,000 $0.493 12,313 Institutional placement under ANREO 12 October 2020 20,525,820 $0.800 16,420,656 Retail placement under ANREO 26 October 2020 11,017,075 $0.800 8,813,660 Issued on conversion of options 2 March 2021 391,500 $0.635 248,661 Issued on conversion of options 15 March 2021 25,000 $0.493 12,313 Share placement 28 April 2021 3,037,580 $1.407 4,274,633 Issued on achievement of milestone 21 May 2021 2,391,865 $1.421 3,400,000 Less: share issue transaction costs - $0.000 (1,673,388) Balance 30 June 2021 132,012,209 80,290,062 Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Share buy-back There is no current on-market share buy-back. Capital risk management The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. The capital risk management policy remains unchanged from the prior year. NOTE 18. OTHER CONTRIBUTED EQUITY Consolidated 2021 2020 $ $ Convertible note – Triaxial 464,000 464,000 On 4 December 2014, the consolidated entity and the convertible note holder (‘Triaxial’) signed a Convertible Note Deed Poll (‘Deed’) which superseded the precedent Loan Agreement between Triaxial shareholders and the consolidated entity. The Deed extinguishes the liability created by the Loan Agreement and provides that the Convertible Notes will convert into a pre-determined number of ordinary shares on the achievement of defined milestones established in the schedule of the Deed. Accordingly the convertible note has been reclassified as an equity instrument rather than debt instrument. NOTE 17. CONTRIBUTED EQUITY (CONTINUED)